Blog

Petros Grivas: My heart goes to people in the areas affected by the LA fires

Vivek Subbiah/X

Jan 11, 2025, 21:25

Petros Grivas: My heart goes to people in the areas affected by the LA fires

Petros Grivas, Clinical Director of the Genitourinary Cancers Program at the University of Washington, shared a post on X by Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, adding:

“My heart goes to people in affected areas; natural disasters like this are a ‘wake-up call’ that nothing is for granted; we need to take care of each other and nature.

Hope for full and fast resolution, thanks for all responders who help save lives and properties!”

Quoting Vivek Subbiah’s post:

“Sending prayers to everyone in LA affected by the fires. I’ve called and checked on many friends and colleagues for their safety – many have been evacuated.

Huge thanks to the brave firefighters and first responders. Your courage and sacrifice are deeply appreciated.

Let’s support each other during this tough time.”

Petros Grivas: My heart goes to people in the areas affected by the LA fires

Dr. Petros Grivas, a board-certified medical oncologist, serves as Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance.

He’s an Associate Professor at the Dept. of Medicine and Associate Member at Fred Hutchinson Cancer Research Center since January 2018. With extensive training and experience, he’s led clinical trials, contributing to FDA approvals for bladder/urothelial cancer treatments.

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer center.

He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.

More posts featuring Petros Grivas and Vivek Subbiah.